Business Description
argenx SE is a Netherlands-based biopharmaceutical company focused on treating autoimmune diseases, with operations spanning the United States, Japan, China, and beyond. Its flagship products, VYVGART and VYVGART HYTRULO, are approved treatments for several serious immune conditions, including generalized myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy. The company maintains a broad pipeline of experimental therapies targeting a range of autoimmune and inflammatory diseases, supported by key partnerships with companies such as Zai Lab, Halozyme Therapeutics, and AbbVie. Founded in 2008 and headquartered in Amsterdam, argenx has grown from a research-stage venture into a commercially active global business.
